Treating obesity: Does antagonism of NPY fit the bill?  by Farooqi, Sadaf
several techniques, including subcellular
fractionation, indirect immunofluores-
cence (IF), and immunoelectron micros-
copy (IEM), that TOR in yeast is associ-
ated with internal membranes, mainly
at or near the plasma membrane (Kunz
et al., 2000; Wedaman et al., 2003). Sev-
eral other yeast TORC1 components
have also been localized to discrete in-
tracellular locations but not within the
nucleus (e.g., Wedaman et al., 2003).
Moreover, the localization pattern of
TOR1 and TOR2 was reported previ-
ously to be insensitive to rapamycin
treatment. Thus, additional studies are
necessary to substantiate the functional
significance of TOR1’s nuclear localiza-
tion. For example, it will be important
to determine whether the same holds
true for TOR2, which can functionally
replace TOR1 within TORC1. However,
in line with Li et al. (2006), signaling
kinases are often found bound to genes
(Pokholok et al., 2006), and mTOR in
mammalian cells has been shown to
shuttle in and out of the nucleus and
this shuttling is important for mTOR sig-
naling (Bachmann et al., 2006). It will be
of interest to determine whether mTOR
binds directly to promoters in mamma-
lian cells.
TOR coordinates the relative activity
of all three RNA polymerases to achieve
the proper stoichiometry of ribosomal
components. Do Li et al. (2006) provide
insight into this aspect of TOR-medi-
ated regulation of ribosome biogene-
sis? A recent report by Laferte et al.
(2006) suggests that rRNA synthesis
by Pol I is a key determinant for tran-
scriptional regulation of all ribosomal
components, including ribosomal pro-
teins and 5S rRNA. Laferte et al.
(2006) constructed a functional, rapa-
mycin-insensitive RNA Pol I by fusing
the Pol I-specific transcription factor
RRN3 to the Pol I subunit RPA43. This
RRN3-Pol I hybrid functioned normally
under good growth conditions. How-
ever, when cells harboring RRN3-Pol I
were treated with rapamycin, or starved
for glucose, 35S rRNA synthesis re-
mained at an elevated level. Surpris-
ingly, these cells also failed to properly
attenuate expression of Pol II-depen-
dent RP genes and Pol III-dependent
5S rRNA synthesis. These results sug-
gest the appealing possibility that TOR
may coordinate the three RNA poly-
merases via Pol I. However, Li et al.
(2006) observed that mutations that al-
ter TOR1-mediated regulation of Pol I
have no effect on expression of RP
genes. Thus, the mechanism of coordi-
nated control of ribosomal components
by TOR remains to be elucidated.
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Figure 1. Transcriptional control of ribosome bio-
genesis by TORC1 in yeast
P R E V I E W STreating obesity: Does antagonism
of NPY fit the bill?
In this issue of Cell Metabolism, Erondu et al. (2006) identify a selective neuropeptide Y5 receptor antagonist that, as
predicted from rodent studies, results in weight loss when administered to overweight and obese human subjects. In
a one-year randomized placebo-controlled clinical trial, the weight loss was modest; the results support the emerging
concept that NPY acts via overlapping and redundant energy homeostasis pathways.Given the disease burden and health
costs associated with the rising preva-260lence of obesity and associated comor-
bidities such as type 2 diabetes, thereis a growing need to find effective, safe,
and well-tolerated therapies to treatCELL METABOLISM : OCTOBER 2006
P R E V I E W SFigure 1. Leptin acts on two distinct populations of neurons located in the arcuate nucleus of the hypothalamus
Neurons expressing pro-opiomelanocortin (POMC) and cocaine- and amphetamine-related transcript (CART) are stimulated by leptin and mediate the anorectic
response (inhibit food intake). Neurons expressing neuropeptide Y (NPY) and agouti-related protein (AGRP) mediate the orexigenic response (increase food intake)
and are inhibited by leptin. These primary neurons synapse with second-order neurons in the paraventricular nucleus (PVN), which express the melanocortin 4 receptor
(MC4R) and the neuropeptide Y1 and Y5 receptors. There are connections between both populations of neurons, which also express the neuropeptide Y1 receptor and
the melanocortin 3 receptor (MC3R).obese patients (Flegal et al., 1998). Al-
though currently available antiobesity
medications are modestly effective, in
some subjects they are accompanied
by significant adverse effects. In recent
years, substantial advances have been
made in the understanding of central
pathways involved in the regulation of
feeding behavior and energy homeosta-
sis (Schwartz et al., 2000). Many of the
agents presently in early-stage clinical
trials act on these central pathways, re-
flecting the consensus that the brain ex-
erts a major influence on feeding behav-
ior and peripheral metabolism through
the autonomic nervous system.
In this issue, Erondu et al. (2006) pres-
ent data on the first clinical trial of an
orally administered neuropeptide Y5 re-
ceptor (NPY5R) antagonist. They show
efficacy in terms of weight loss at 12
weeks and in an extended study at 52
weeks. However, the amount of weight
lost in the long-term study was not suffi-
ciently clinically significant for the agentCELL METABOLISM : OCTOBER 2006to be considered as a feasible monother-
apy for obesity.
Neuropeptide Y (NPY) contains 36
amino acid residues and is one of the
most abundant peptides in the brain.
Although NPY has been implicated in
cardiovascular regulation, the control of
neuroendocrine axes, affective disor-
ders, seizures, and memory retention,
its most noticeable effect is the stimula-
tion of food intake after central adminis-
tration, and it is one of the most potent
orexigenic peptides known (Lin et al.,
2004). When administered chronically,
NPY produces an increase in food intake,
decreased thermogenesis, and obesity.
The hypothalamic arcuate nucleus (ARC)
is the major site of expression for NPY
within neurons that project to the para-
ventricular nucleus (PVN), dorsomedial
hypothalamus (DMH), and lateral hypo-
thalamus (LH) as well as other sites.
NPY synthesis and secretion are upregu-
lated in energy-deficient states such as
starvation, lactation, and physical exer-cise and in rodent models that lack leptin
(ob/ob mice) and its receptor (db/db
mice) (Lin et al., 2004). Fasting activates
the NPY neurons that express the long
signaling isoform of the leptin receptor
(Baskin et al., 1999); a primary physiolog-
ical role for the arcuate NPY neuronsmay
thus be to restore normal energy balance
and body fat stores under conditions of
energy deficit, the signals of which are
falling leptin and/or insulin (Schwartz
et al., 2000). Inhibition of the synthesis
of NPY in the ARC and its subsequent
release into the PVN, the most abundant
projection, may thus partly explain the
ability of leptin to induce hypophagia and
weight loss (Figure 1).
NPY and its two other family members,
peptide YY (PYY) and pancreatic poly-
peptide (PP), exert their effects through
five known G protein-coupled receptors:
Y1, Y2, Y4, Y5, and Y6 (Fetissov et al.,
2004). Although the large number of Y
receptors has made it difficult to delin-
eate their individual contributions, recent261
P R E V I E W Sstudies analyzing NPY and Y receptor-
overexpressing, knockout, and condi-
tional-knockout mouse models have
started to unravel some of the complexity
(Lin et al., 2006). Analogs of NPY with
high selectivity for the Y1 and Y5 recep-
tor subtypes strongly stimulate food in-
take in rodents, and i.c.v. administra-
tion of specific Y5 receptor agonists
increases food intake and body weight
in mice (Parker et al., 2000).
Eronduet al. (2006) report the first stud-
ies in humans using the selective NPY5R
antagonist MK-0557. They show that this
compound selectively binds to the Y5R in
the nanomolar range in vitro, with no se-
lective binding to the other NPY receptor
subtypes. They observe some nonselec-
tive binding at the adenosineA1 receptor,
the serotonergic 5HT2B receptor, and a
monoamine transporter in the micromo-
lar range, although whether this binding
would have any physiological relevance
is unclear. In lean mice fed a high-fat
(31%) diet, MK-0557 caused a 40% re-
duction in body weight gain (rather than
weight loss) and a 5% reduction in cumu-
lative food intake compared to control
mice.
Following on from these preclinical
studies, the authors went on to demon-
strate in vivo receptor occupancy by im-
aging the brain in human volunteers us-
ing positron emission tomography (PET)
following the administration of a radiola-
beled NPY5R-selective PET ligand with
a structure similar to MK-0557. These
data were consistent with their phar-
macokinetic data and guided the choice
of optimal dosing for their subsequent
clinical studies.
After a 6 week run in with dietary and
exercise advice, as is conventional in
clinical trials of weight-loss medication,
the authors administered MK-0557 to
547 obese subjects, who showed statis-
tically significant weight loss at 12 weeks
compared to subjects treated with pla-
cebo. These observations clearly indi-
cate that antagonizing the Y5R induces
weight loss in humans. The authors
then undertook a long-term trial over 52
weeks in 1661 subjects (832 completed).
Primary endpoints used to evaluate anti-
obesity drugs most frequently include
mean weight loss, percentage weight262loss, and proportion of patients losing
R5% and R10% of initial body weight;
secondary endpoints conventionally in-
clude reduction in body fat, risk factors
for cardiovascular disease, and the inci-
dence of diseases such as type 2 diabe-
tes. A major obstacle to the evaluation of
weight-loss clinical trials is the potential
bias resulting from low study completion
rates, and this effect may well be relevant
in the trials conducted by Erondu et al.
Other inherent potential sources of bias
include run-in periods and subsequent
patient selection based on compliance
or initial weight loss (Patel et al., 2006).
Nonetheless, Erondu et al. showed a
mean weight loss of 3.4 kg in those who
completed the trial, which was signifi-
cantly greater than the weight loss seen
in the placebo-treated group over 52
weeks. Significantly more subjects lost
R5% and R10% of initial body weight
with the NPY5R antagonist than did so
on placebo. The authors conclude, how-
ever, that the magnitude of the weight
loss observed was not clinically signifi-
cant, and this conclusion is supported
by the observation that there were no
significant improvements in secondary
endpoints such as glucose and lipid
levels and blood pressure measure-
ments.
Are these results unexpected? As the
authors point out, it is well known that
the NPY-mediated feeding response may
be mediated by more than one recep-
tor subtype, and biological redundancies
are likely to exist between Y1 and Y5
receptor signaling (Parker et al., 2002).
In a recent study by Herzog and col-
leagues (Lin et al., 2006), long-term hypo-
thalamic overexpression of NPY in mice
resulted in a marked increase in food
intake and weight gain that persisted
in Y1 and Y2 receptor knockouts, Y2/Y4
double knockouts, and Y1/Y2/Y4 triple
knockouts. Also, increasing evidence
points to the existence of other as yet un-
identified Y receptors, which may medi-
ate NPY’s orexigenic actions, and it
remains possible that, under certain
physiological conditions, NPY may bind
and activate receptors for which it nor-
mally has no or only low affinities.
The only drugs currently approved for
the management of obesity in adults aresibutramine, orlistat, and, more recently,
rimonabant, each of which has been
demonstrated to be effective in long-
term randomized controlled trials. While
several potential new obesity therapies
that act through the CNS pathways or
peripheral adiposity signals are in early-
phase clinical trials, the study by Erondu
and colleagues (2006) serves to remind
us that manipulation of the homeostatic
mechanisms involving hypothalamic/
brainstem pathways for a clinically signif-
icant outcome in obese patients remains
a major challenge.
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